CCT Impact

Youngevity Rings in Wellness Week 2020 at Nasdaq Closing Bell

Youngevity® International, Inc. (NASDAQ: YGYI), a leading multi-channel lifestyle company operating in three distinct business segments including a commercial coffee enterprise and a commercial hemp enterprise, was recognized by Nasdaq as a 2020 “Wellness Week” company and selected to ring the closing bell on January 7, 2020 at the Nasdaq MarketSite in Times Square. (PRNewsfoto/Youngevity International, Inc.) On January......
Cannabis News Market Watch

Tilray Inc. Files For Proposed IPO on Nasdaq

Tilray Inc., A Canadian cannabis cultivator, processor, and distributor, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for a proposed initial public offering (IPO) on the Nasdaq Global Select Market. The ticker symbol “TLRY” will be used, and will offer shares of its Class 2......
CCT Impact Hemp News

Investing in Public Companies that Sell CBD

Interest in cannabidiol (CBD) has taken off over the past five years since CNN highlighted its promise in the documentary Weed. GW Pharma (NASDAQ: GWPH) has submitted a New Drug Application for its CBD-based Epidiolex (which has received Orphan Drug Status in the European Union) with the FDA. If it......
Cannabis News Global Health Hemp News Market Watch

GW Pharmaceuticals Receives Orphan Drug Designation from the European Medicines Agency (EMA)

On February 27, 2018, GW Pharmaceuticals, PLC (Nasdaq:GWPH) (“GW) announced that the European Medicines Agency (EMA) has granted orphan drug designation for cannabidiol (CBD) for the treatment of tuberous sclerosis (TS). GW has started a Phase 3 clinical trial of Epidiolex® (cannabidiol) as an adjunctive therapy for the treatment of......
CCT Impact

The Cronos Group Makes Move to the NASDAQ

The Cronos Group (TSX-V: MJN) (NASDAQ: PRMCF) has announced that the company’s common shares in the United States will begin trading on the NASDAQ tomorrow morning. The NASDAQ is a global electronic marketplace for investors to buy and sells securities. Companies currently trading on the NASDAQ include someone the most......
Current News Health Market Watch

GW Pharma’s New Compound GWP42006 Fails Initial Trial Testing

On February 21, 2018 GW Pharmaceuticals PLC (Nasdaq:GWPH) (“GW,”) announced that a Phase 2a proof of concept study of a pipeline compound GWP42006 in adult patients with focal seizures did not meet its primary endpoint.  The trial was conducted outside the United States, primarily in Eastern Europe.  In the trial’s......